WebPalcitoclax (APG-1252) +/− ruxolitinib: Bcl-2/xL inhibitor-Dose-limiting toxicity (Time frame: 28 days)-Spleen volume measurement reduction. NCT02098161: LCL161 in treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocytosis myelofibrosis: Active, not recruiting: MF (primary, post-ET or ... WebPalcitoclax (APG-1252) was being developed to reduce on-target platelet toxicity without diminishing antitumor potency. Methods: The phase 1 study was to evaluate the safety/tolerability, pharmacokinetics (PK), and preliminary efficacy (assessed per RECIST 1.1) of palcitoclax in US patients with metastatic small-cell lung cancer (SCLC) or other ...
(ASCO2024) Ascentage Pharma Presents Latest Clinical …
WebDrugs Palcitoclax (Primary) Indications Brain metastases; Small cell lung cancer; Solid tumours Focus Adverse reactions Sponsors Ascentage Pharma Most Recent Events 24 Aug 2024 Status changed from recruiting to discontinued. WebMay 31, 2024 · About Palcitoclax or APG-1252 APG-1252 is a novel, highly potent, small-molecule drug that was discovered and is being developed by Ascentage Pharma. APG … cot gia
First-in-human study of palcitoclax (APG-1252), a novel dual Bcl …
WebAmong them, palcitoclax (APG-1252) has shown reduced toxicity on platelets (Lakhani et al., 2024) and is currently being tested in the treatment of MF (NCT04354727). Evasion from programmed cell death is a hallmark of cancer and can be achieved in cancer cells by overexpression of inhibitor of apoptosis proteins (IAPs). WebPreclinical studies have shown that palcitoclax can achieve tumor suppression in multiple xenograft models, including ALL, SCLC, colorectal and breast cancer [33, 34]. We examined 1 clinical trial ... WebJan 13, 2024 · Palcitoclax is a highly potent Bcl-2 famil y protein antago-nist and, like navitoclax, targe ts mainly the Bcl-2 and Bcl-xL antiapoptotic proteins. It was dev eloped in an effor t to . mafell duo dübler